IsoPlexis Announces Research Collaboration with Nektar Therapeutics

IsoCode, IsoPlexis’ single-cell precision platform, captured novel data from CAR-T products developed by Novartis Pharmaceuticals (Novartis), leading to IsoPlexis’ development of new bioinformatics tools for visualizing high-dimensional, single-cell proteomics data. These new tools enable researchers to better compare key differences between products, and more easily analyze highly-multiplexed, single CAR-T cell functional profiles to gain insight into CAR-T product potency and cytokine mediated immuno-toxicity. Researchers used IsoCode to analyze genetically re-engineered CAR-T cells designed to target CD19, a promising treatment for B-cell malignancies, including most cases of non-Hodgkin lymphoma and some types of leukemia. The large quantity of precise, high-quality data required IsoPlexis to develop new bioinformatics tools, which researchers used to better visualize the polyfunctional profiles of each individual CAR-T product.

Share This Article
Be in the Know.
Subscribe to the IsoPlexis Blog
Join 10,000+ top scientists and receive industry pioneers' backed data straight to your inbox.
Your data is in safe hands! We'll never share or sell your data to any third parties, and you may unsubscribe at any time.